Matthew Piscitelli is a member of DLA Piper’s FDA Regulatory Group where he advises clients who develop a wide range of products, with an emphasis on manufacturers of medical devices, drugs, and biological products.

Matthew counsels clients in regulatory matters across all stages of the product life cycle, from research and development to nonclinical testing, clinical trials, premarket clearance and approval, manufacturing, labeling compliance, and post-market surveillance. Matthew represents clients across a broad range of agency proceedings such as Orange Book listing disputes, citizen petitions, establishment inspections, and enforcement actions.

Matthew has extensive experience in conducting regulatory due diligence on behalf of companies seeking to acquire or invest in companies with a portfolio of FDA-regulated products.